Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

NP49425 Generic and Biosimilar Transition Medicines

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

This public procurement record has 5 releases in its history.

AwardUpdate

30 Mar 2026 at 14:46

Award Notice
Award

19 Dec 2025 at 16:55

Award Notice
TenderUpdate

04 Sep 2025 at 17:01

Tender Notice
Tender

21 Aug 2025 at 10:55

Tender Notice
Planning

05 Aug 2025 at 16:26

Planning Notice
Summary of the contracting process

The procurement process for NP49425 Generic and Biosimilar Transition Medicines is spearheaded by The Common Services Agency, famously known as NHS National Services Scotland (NSS), based in Edinburgh, UK. The tender process has recently reached the contract update stage, with the awarded contract being active as of 18 December 2025. This procurement covers the broad category of pharmaceutical products, with a focus on medicines for NHS Scotland. The goods are delivered across the UKM region, and the contract pertains to various lots including cytokine modulators, cardiovascular and respiratory medicines, and cancer medicines. Notably, the framework agreement spans a potential duration of 48 months, inclusive of possible extensions. The procurement method employed is the open procedure, ensuring a competitive process adhering to the Public Contracts (Scotland) Regulations 2015.

This tender offers substantial growth opportunities, particularly for businesses that specialise in pharmaceuticals, generic medicines, and biotechnology. Companies with established supply chains and those able to meet stringent technical specifications, such as the possession of a UK Marketing Authorisation and ISO 9001 certification, are well-positioned to compete. Additionally, firms with a strategic focus on addressing the climate change emergency through carbon emission reduction plans can leverage this framework to establish strong partnerships with NHS Scotland. The multi-supplier framework agreement encourages a diverse range of participants, extending chances for both large and medium-sized pharmaceutical companies to collaborate and successfully supply a vast array of medicines vital to public health.

How relevant is this notice?

Notice Information

Notice Title

NP49425 Generic and Biosimilar Transition Medicines

Notice Description

Supply of generic and biosimilar transition medicines to NHS Scotland.

Lot Information

Cancer Medicines (Group 1)

Supply of cancer medicines (group 1) to NHS Scotland. The Authority has awarded this Lot as a ranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty-six (36) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Cytokine Modulators (Golimumab, Tocilizumab, and Etanercept)

Supply of generic cand biosimilar transition medicines to NHS Scotland. The Authority has awarded this Lot as an unranked multi supplier Framework Agreement per line to six (6) Framework Participants. Full details of Goods and volumes can be found within the ITT (Invitation to Tender) documents.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty-five (35) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Cytokine Modulators (Omalizumab)

Supply of cytokine modulators (omalizumab) to NHS Scotland. The Authority has awarded this Lot as an unranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty-five (35) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Gastrointestinal, Endocrine, Blood, and Multiple Sclerosis Medicines

Supply of gastrointestinal, endocrine, blood, and multiple sclerosis medicines to NHS Scotland. The Authority has awarded this Lot as a ranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty (30) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Denosumab (Osteoporosis) and Ferric Carboxymaltose

Supply of denosumab (osteoporosis) and ferric carboxymaltose to NHS Scotland. The Authority has awarded this Lot as an unranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty (30) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Apremilast

Supply of apremilast to NHS Scotland. The Authority has awarded this Lot as a ranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of twenty-seven (27) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Cardiovascular and Respiratory Medicines

Supply of cardiovascular and respiratory medicines to NHS Scotland. The Authority has awarded this Lot as a ranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of twenty-one (21) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Nintedanib

Supply of nintedanib to NHS Scotland. The Authority has awarded this Lot as a ranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of twenty-one (21) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Cancer Medicines (Group 2)

Supply of cancer medicines (group 2) to NHS Scotland. The Authority has awarded this Lot as an unranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of thirty-six (36) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Psychiatry and Neurology Medicines

Supply of psychiatry and neurology medicines to NHS Scotland. The Authority has awarded this Lot as a ranked multi supplier Framework Agreement per product line.

Renewal: The Framework Agreement includes the option to extend for any number of periods, up to a maximum overall period of seventeen (17) months, upon giving not less than three (3) months written notice, such notice to expire no later than the date the Framework Agreement is due to expire.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-0581ea
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/029168-2026
Current Stage
Award
All Stages
Planning, Tender, Award

Procurement Classification

Notice Type
Planning Notice
Procurement Type
Framework
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
Not specified
Awardee Scale
Large

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
£234,969,011 £100M-£1B
Lots Value
£234,969,011 £100M-£1B
Awards Value
Not specified
Contracts Value
£128,207,480 £100M-£1B

Notice Dates

Publication Date
30 Mar 20264 months ago
Submission Deadline
22 Sep 2025Expired
Future Notice Date
15 Aug 2025Expired
Award Date
18 Dec 20258 months ago
Contract Period
1 Feb 2026 - 30 Sep 2028 2-3 years
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Cancelled
Awards Status
Active
Contracts Status
Active

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
EDINBURGH
Postcode
EH12 9EB
Postcode Area
Edinburgh
Country
Scotland
Major Region (ITL 1)
TLM Scotland
Basic Region (ITL 2)
TLM1 East Central Scotland
Small Region (ITL 3)
TLM13 City of Edinburgh
Delivery Location
TLM Scotland
Local Authority
City of Edinburgh
Electoral Ward
Drum Brae/Gyle
Westminster Constituency
Edinburgh South West

Supplier Information

Number of Suppliers
39
Supplier Names

AOP Orphan Ltd

Accord Healthcare Ltd

Amarox Limited

Amgen Ltd

Biocon Pharma UK Ltd

Brown and Burk

CST Pharma Ltd

Celix Pharma Ltd.

Celltrion Healthcare United Kingdom Limited

Chiesi Limited

Chiesi Ltd

Dr Falk Pharma UK Ltd

Dr Reddy's Laboratories (UK) Ltd

Ferring Pharmaceuticals Limited

Fresenius Kabi

Fresenius Kabi Ltd

Gedeon Richter UK Ltd

Glenmark Pharmaceuticals Europe Ltd

Janssen-Cilag Ltd

Lupin Healthcare UK Ltd

MSN Labs

Mercury Pharma Group

Mercury Pharmaceuticals Limited

Perennial Pharma Ltd

Pfizer

Roche Products Ltd

SERB SA

STADA UK - Thornton & Ross

Samsung Bioepis Ltd

Sandoz

Takeda UK Limited

Teva UK Ltd

Theramex HQ UK Ltd

Viatris UK Healthcare Ltd

Vifor Pharma UK Limited

Wockhardt UK Limited

Zentiva Pharma UK Ltd

Zentiva UK

Zydus Pharmaceuticals UK Ltd

Further Information

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...